DexCom, Inc. (NASDAQ:DXCM) COO Sells $228,920.94 in Stock

DexCom, Inc. (NASDAQ:DXCMGet Free Report) COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

DexCom Stock Up 1.4 %

NASDAQ DXCM traded up $1.19 on Thursday, reaching $87.62. The stock had a trading volume of 2,123,429 shares, compared to its average volume of 3,649,357. The business has a 50 day moving average price of $80.22 and a 200 day moving average price of $76.59. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a market capitalization of $34.22 billion, a price-to-earnings ratio of 52.47, a P/E/G ratio of 2.23 and a beta of 1.12.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. JPMorgan Chase & Co. lifted their target price on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Leerink Partners decreased their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Royal Bank of Canada reduced their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Canaccord Genuity Group boosted their price objective on DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Finally, StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $99.29.

Get Our Latest Report on DexCom

Institutional Trading of DexCom

Institutional investors and hedge funds have recently made changes to their positions in the stock. Principal Securities Inc. lifted its position in shares of DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock worth $316,000 after purchasing an additional 135 shares during the last quarter. B. Riley Wealth Advisors Inc. increased its holdings in shares of DexCom by 4.3% during the second quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock worth $445,000 after buying an additional 162 shares in the last quarter. Crossmark Global Holdings Inc. increased its position in DexCom by 1.0% in the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after purchasing an additional 182 shares during the period. GPS Wealth Strategies Group LLC increased its position in DexCom by 13.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock worth $123,000 after purchasing an additional 185 shares during the period. Finally, Peterson Wealth Services grew its position in shares of DexCom by 7.1% during the 4th quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company’s stock worth $236,000 after buying an additional 201 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

(Get Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Recommended Stories

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.